Opinion|Videos|March 20, 2025
Academic Perspectives on Systemic Therapy for Advanced uHCC
Author(s)Amit Mahipal, MD
An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy through imaging, α-fetoprotein levels, and tolerability. Treatment decisions are guided by response assessment, adverse events, and liver function. First-line (1L) options include tyrosine kinase inhibitors and immunotherapy combinations, with promising trials exploring novel immune combinations and targeted approaches that may reshape the treatment landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What remaining clinical pearls can you share regarding systemic therapy treatment approaches for patients with advanced uHCC?
- How do you evaluate treatment success over time, and what are key indicators that guide decisions regarding treatment modifications or sequencing?
- What trials are you anticipating that might affect the 1L treatment of uHCC?
Advertisement
Related to this article
The FDA assigned an April 9, 2027, PDUFA date to rivoceranib plus camrelizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
2
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
3
Oncologists Discuss Ibrutinib Switching and Fixed-Duration Therapy in CLL
4
Novocure’s Optune Mya Gets FDA Not Approvable Letter
5